REDLAMP 8: Does a Geriatric Assessment Hold Prognostic Value for Patients with Aggressive NHL?

Diffuse large B-cell lymphoma is the most common non-Hodgkin lymphoma (NHL). It is an aggressive disease that often affects older patients.The journal Leukemia & Lymphoma, recently published a study investigating whether a geriatric assessment would be of prognostic value for patients with aggressive NHL. This included assessments of nutrition, frailty, cognitive ability, performance status, and relevant laboratory values. In this video, new faculty member, Dr. Sarah Rutherford explains the results of this study, and offers takeaways for older patients with aggressive NHL.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2064.

Dr. John Leonard Discusses Use of Lenalidomide + Rituximab in Patients with Recurrent Follicular Lymphoma

In this video clip from OncLive Lymphoma Program Director, John Leonard, MD discusses the combination of lenalidomide and rituximab in patients with recurrent follicular lymphoma.

Lymphoma Patient Education Forum – Less than One Week Away

On Monday, June 29th the Lymphoma Program at Weill Cornell Medical College invites you to hear from our experts about the latest advances in lymphoma treatment & nutrition:

Patient Edu Flyer Digital 052815